Skip to main content

Table 1 Demographic and clinical data at baseline in the intention-to-treat population

From: Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Characteristic N = 99
Male, n (%) 66 (66.7)
White/Caucasian ethnicity, n (%) 98 (99.0)
Median age, years (range) 64.1 (34-82))
ECOG status, n (%)  
  0 51 (51.5)
  1 48 (48.5)
Tumor status at diagnosis, n (%)  
  T1 1 (1.0)
  T2 6 (6.1)
  T3 43 (43.4)
  T4 25 (25.3)
  Unknown 24 (24.2)
Node status at diagnosis, n (%)  
  N0 22 (22.2)
  N1 24 (24.2)
  N2 25 (25.3)
  Unknown 28 (28.3)
Metastases status at diagnosis, n (%)  
  M0 21 (21.2)
  M1 76 (76.8)
  Unknown 2 (2.0)
Primary tumor site, n (%)  
  Colon 59 (59.6)
  Rectum 40 (40.4)
Metastases sites*, n (%)  
  Liver 87 (87.9)
  Lung 39 (39.4)
  Lymph nodes 27 (27.3)
  Other 17 (17.1)
Prior therapy, n (%)  
  Adjuvant chemotherapy (FOLFOX) 9 (9.1%)
  Neoadjuvant chemo-radiotherapy for rectal cancer 7 (7.1%)
  Surgery 48 (48.5%)
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group, ITT Intention to treat, Q1-Q3 Interquarile range.
  2. *A patient may had metastases in more than one organ.